for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sol Gel Technologies Ltd

SLGL.OQ

Latest Trade

8.13USD

Change

-0.17(-2.05%)

Volume

329

Today's Range

8.00

 - 

8.13

52 Week Range

5.61

 - 

11.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Sol Gel Technologies Reports Qtrly Loss Per Share $0.26

Aug 13 (Reuters) - Sol Gel Technologies Ltd <SLGL.O>::SOL-GEL TECHNOLOGIES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATE.Q2 REVENUE $7.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $6.4 MILLION.TWIN PHASE 3 TRIALS ARE FULLY ENROLLED AND REMAIN ON TRACK TO REPORT RESULTS IN 4Q19.QTRLY LOSS PER SHARE $0.26.

Sol-Gel Announces Positive Top-Line Results From Epsolay Phase 3 Program In Papulopustular Rosacea

July 8 (Reuters) - Sol Gel Technologies Ltd <SLGL.O>::SOL-GEL ANNOUNCES POSITIVE TOP-LINE RESULTS FROM EPSOLAY® PHASE 3 PROGRAM IN PAPULOPUSTULAR ROSACEA.SOL GEL TECHNOLOGIES LTD -.SOL GEL TECHNOLOGIES LTD - FAVORABLE SAFETY AND TOLERABILITY PROFILE, SIMILAR TO VEHICLE.SOL GEL TECHNOLOGIES LTD - ALL PRIMARY AND SECONDARY ENDPOINTS ACHIEVED IN BOTH PHASE 3 CLINICAL TRIALS.SOL GEL TECHNOLOGIES LTD - RAPID EFFICACY DEMONSTRATED, WITH STATISTICAL SIGNIFICANCE REACHED AS EARLY AS WEEK 2 COMPARED WITH VEHICLE.SOL GEL TECHNOLOGIES - WHILE CO EXPECTED TO SEE STRONG EFFICACY AND TOLERABILITY WITH EPSOLAY, RAPID EFFICACY WAS STANDOUT IN PHASE 3 STUDIES.SOL GEL TECHNOLOGIES LTD - IN TWO 12-WEEK CLINICAL STUDIES, SGT 54-01 AND SGT 54-02, EPSOLAY DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT.SOL GEL TECHNOLOGIES LTD - ADVERSE EVENTS FOR EPSOLAY WERE PRIMARILY MILD TO MODERATE IN SEVERITY.SOL GEL TECHNOLOGIES LTD - IN Q4 OF 2019, TOP-LINE PHASE 3 RESULTS ARE EXPECTED FOR TWIN.SOL GEL TECHNOLOGIES LTD - THERE WAS NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS FOR EPSOLAY.SOL GEL - ESTIMATES REVENUE FOR Q2 2019 ATTRIBUTABLE TO SALES OF PARTNERED GENERIC PRODUCT, ACYCLOVIR CREAM, 5%, WITH PERRIGO TO BE ABOUT $7.0 MILLION.SOL GEL TECHNOLOGIES - AS OF JUNE 30, 2019, CO'S CASH, CASH EQUIVALENTS, DEPOSITS AND MARKETABLE SECURITIES IS EXPECTED TO BE ABOUT $49.8 MILLION.

Sol-Gel Technologies Announces Seventh Agreement For Generic Product Candidates With Perrigo

Sol Gel Technologies Ltd <SLGL.O>::SOL-GEL TECHNOLOGIES ANNOUNCES SEVENTH AGREEMENT FOR GENERIC PRODUCT CANDIDATES WITH PERRIGO.SOL GEL TECHNOLOGIES LTD - ENTERED INTO A SEVENTH COLLABORATIVE AGREEMENT WITH PERRIGO ISRAEL.SOL GEL TECHNOLOGIES LTD - PERRIGO HAS AGREED TO COMMERCIALIZE GENERIC PRODUCT CANDIDATES IN UNITED STATES..SOL GEL TECHNOLOGIES LTD - SOL-GEL AND PERRIGO WILL SHARE DEVELOPMENT COSTS AND GROSS PROFITS GENERATED FROM SALES OF GENERIC PRODUCT CANDIDATES.

Sol Gel Technologies Reports Qtrly Loss Per Ordinary Share $0.30

May 22 (Reuters) - Sol Gel Technologies Ltd <SLGL.O>::SOL-GEL TECHNOLOGIES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATE.Q1 REVENUE $6.4 MILLION.Q1 REVENUE ESTIMATE $572,000 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, SOL-GEL HAD $9.2 MILLION IN CASH, CASH EQUIVALENTS AND DEPOSITS.SOL GEL TECHNOLOGIES - EXPECTS EXISTING CASH RESOURCES WILL ENABLE FUNDING OF OPERATIONAL AND CAPITAL EXPENDITURE REQUIREMENTS THROUGH MID-2020.QTRLY LOSS PER ORDINARY SHARE $0.30.

Sol Gel Technologies Ltd Files For Mixed Shelf Of Up To $120 Million

March 28 (Reuters) - Sol Gel Technologies Ltd <SLGL.O>::SOL GEL TECHNOLOGIES LTD FILES FOR MIXED SHELF OF UP TO $120 MILLION – SEC FILING.

Sol Gel Reports $63 Mln In Cash And Cash Equivalents, Deposits And Marketable Securities

March 21 (Reuters) - Sol Gel Technologies Ltd <SLGL.O>::SOL-GEL TECHNOLOGIES REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.SOL GEL TECHNOLOGIES LTD - AS OF DECEMBER 31, 2018 HAD $63.0 MILLION IN CASH AND CASH EQUIVALENTS, DEPOSITS AND MARKETABLE SECURITIES.

Perrigo Announces FDA Final Approval For Its AB Rated Generic Version Of Zovirax Cream 5 Pct

Feb 6 (Reuters) - Perrigo Company PLC <PRGO.N>::PERRIGO ANNOUNCES FDA FINAL APPROVAL FOR ITS AB RATED GENERIC VERSION OF ZOVIRAX® CREAM 5%.PERRIGO COMPANY PLC - COMPANY ANTICIPATES LAUNCHING GENERIC VERSION OF ZOVIRAX CREAM 5% THIS MONTH..

Sol-Gel Technologies announces sixth agreement for a generic product candidate with Perrigo

Dec 4 (Reuters) - Sol Gel Technologies Ltd <SLGL.O>::SOL-GEL TECHNOLOGIES ANNOUNCES SIXTH AGREEMENT FOR A GENERIC PRODUCT CANDIDATE WITH PERRIGO.SOL GEL TECHNOLOGIES - ENTERED INTO SIXTH COLLABORATIVE AGREEMENT WITH PERRIGO ISRAEL FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF GENERIC PRODUCT CANDIDATE.

Sol Gel Technologies Ltd - QTRLY Basic And Diluted Loss Per Ordinary Share $0.40

Sol Gel Technologies Ltd <SLGL.O>::SOL-GEL TECHNOLOGIES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.SOL GEL TECHNOLOGIES LTD - AS OF SEPT 30, HAD $14.3 MILLION IN CASH, CASH EQUIVALENTS & DEPOSITS & $59.2 MILLION IN MARKETABLE SECURITIES, FOR $73.5 MILLION..SOL GEL TECHNOLOGIES LTD - QTRLY BASIC AND DILUTED LOSS PER ORDINARY SHARE $0.40.

Sol-Gel Technologies Ltd - Additional Collaborative Agreement With Perrigo

Nov 1 (Reuters) - Perrigo Company PLC <PRGO.N>::SOL GEL TECHNOLOGIES LTD - ADDITIONAL COLLABORATIVE AGREEMENT FOR A GENERIC PRODUCT CANDIDATE WITH PERRIGO.SOL GEL TECHNOLOGIES LTD - PERRIGO WILL SEEK REGULATORY APPROVAL WITH FDA FOR GENERIC PRODUCT CANDIDATE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up